CVRx: associated payment is ~$45K for outpatient procedures

CVRx: associated payment is ~$45K for outpatient procedures

CVRx (NASDAQ: CVRX), a commercial-stage medical device company, has received positive news regarding the reimbursement for its Barostim implant procedures. The Centers for Medicare and Medicaid Services (CMS) has proposed to maintain the Barostim implant procedure in the New Technology Ambulatory Payment Classification (APC) 1580, with an approximate payment of $45,000 for procedures performed in the outpatient setting [1].

This proposal follows two significant reimbursement developments in the past nine months. As of October 1, 2024, Barostim was assigned to a higher-paying MS-DRG for inpatient procedures. Additionally, Barostim will transition from Category III to Category I CPT codes for physician payments, effective January 1, 2026 [2]. These updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.

Kevin Hykes, President and CEO of CVRx, expressed appreciation for CMS’s proposal, stating that it ensures appropriate payment for the Barostim implant procedure. He noted that these reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, will support the company’s progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction [1].

The final 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule is expected to be published in November 2025, with implementation planned for January 2026. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC [1].

References:
[1] https://www.stocktitan.net/news/CVRX/cv-rx-announces-positive-news-on-outpatient-payment-for-yk009232cfuj.html
[2] https://www.globenewswire.com/news-release/2025/07/16/3116282/0/en/CVRx-Announces-Positive-News-on-Outpatient-Payment-for-Barostim.html